UPS announced a $48 million investment in 27 temperature-controlled freight cross-dock facilities around the globe, strengthening its position as the world's number one provider of complex healthcare logistics. The facilities are located in key U.S. and international markets, including Europe, Asia and the Americas, and are optimized for speed and short-term storage between air and ground movements while maintaining specific temperature requirements. All facilities are compliant with IATA CEIV Pharma certification, and the integrated network eliminates handoffs between providers to reduce risk and increase control for high-value, temperature-sensitive therapies. The investment comes as industry demand for temperature-sensitive biologics is projected to expand at an 8.3% compound annual growth rate through 2033, reaching an estimated $39.1 billion, and as roughly one in three newly approved drugs is a biologic with more than 85% requiring temperature-controlled handling. UPS's cross-dock expansion builds on previous acquisitions including Bomi Group, Frigo Trans, BPL, and Andlauer Healthcare Group, and follows the recent expansion of its Incheon, Korea air hub to support fast-growing pharmaceutical trade flows.
United Parcel Service IncUPS invests $48M in temperature-controlled facilities to meet growing demand for biologics, projected to grow 8.3% CAGR.